Biomerieux SA
PAR:BIM
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
88.75
110.3
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BIM stock under the Base Case scenario is 104.34 EUR. Compared to the current market price of 98.9 EUR, Biomerieux SA is Undervalued by 5%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Biomerieux SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BIM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Show Overview: BioMérieux SA: Pioneering Diagnostics for a Healthier World BioMérieux SA, a French multinational founded in 1963, stands at the forefront of the global diagnostics industry, driving innovation in infectious disease testing and food safety. With a mission to improve public health through advanced diagnostic solutions, the company has developed a robust portfolio of products that include molecular biology, microbiology, and immunoassays. Its cutting-edge technologies empower h...
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Biomerieux SA
Balance Sheet Decomposition
Biomerieux SA
Current Assets | 2.2B |
Cash & Short-Term Investments | 272.2m |
Receivables | 928m |
Other Current Assets | 1B |
Non-Current Assets | 3.1B |
Long-Term Investments | 154.9m |
PP&E | 1.6B |
Intangibles | 1.2B |
Other Non-Current Assets | 130.7m |
Current Liabilities | 1B |
Accounts Payable | 215.7m |
Short-Term Debt | 19.8m |
Other Current Liabilities | 765.7m |
Non-Current Liabilities | 450.1m |
Long-Term Debt | 373.4m |
Other Non-Current Liabilities | 76.7m |
Earnings Waterfall
Biomerieux SA
Revenue
|
3.8B
EUR
|
Cost of Revenue
|
-1.7B
EUR
|
Gross Profit
|
2.1B
EUR
|
Operating Expenses
|
-1.6B
EUR
|
Operating Income
|
519.5m
EUR
|
Other Expenses
|
-108.2m
EUR
|
Net Income
|
411.3m
EUR
|
Free Cash Flow Analysis
Biomerieux SA
EUR | |
Free Cash Flow | EUR |
BIM Profitability Score
Profitability Due Diligence
Biomerieux SA's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
Biomerieux SA's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
BIM Solvency Score
Solvency Due Diligence
Biomerieux SA's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Biomerieux SA's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIM Price Targets Summary
Biomerieux SA
According to Wall Street analysts, the average 1-year price target for BIM is 121.65 EUR with a low forecast of 91.91 EUR and a high forecast of 136.5 EUR.
Dividends
Current shareholder yield for BIM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
BIM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
The intrinsic value of one BIM stock under the Base Case scenario is 104.34 EUR.
Compared to the current market price of 98.9 EUR, Biomerieux SA is Undervalued by 5%.